Taylor P. GSK, J&J say monthly injection keeps HIV controlled. PMLiVE 2019:8 de marzo. [Ref.ID 103051]

Chambers HF. Omadacycline — The newest tetracycline. N Engl J Med 2019;380:7 de febrero. [Ref.ID 103037]

Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and management of penicillin allergy. A review. JAMA 2019;321:15 de enero. [Ref.ID 103008]

Blumenthal KG, Lu N, Zhang Y, Li Y, Walensky RP, Choi HK. Risk of meticillin resistant Staphylococcus aureus and Clostridium difficile in patients with a documented penicillin allergy: population based matched cohort study. BMJ 2018;361:27 de junio. [Ref.ID 102750]

Silverman E. STAT Plus: Novartis is the latest big drug maker to exit antibiotic research. STAT Daily Recap 2018:3. [Ref.ID 102708]

Mitjà O, Godornes C, Houinei W, Kapa A, Paru R, Abel H, González-Beiras C, Bieb SV, Wangi J, Barry AE, Sanz S, Bassat Q, Lukehart SA. Re-emergence of yaws after single mass azithromycin treatment followed by targeted treatment: a longitudinal study. Lancet 2018;391:21 de abril. [Ref.ID 102568]

Šmajs D, Pospíšilová P. Macrolide resistance in yaws. Lancet 2018;391:21 de abril. [Ref.ID 102567]

King LM, Sanchez GV, Bartoces M, Hicks A, Fleming-Dutra KE. Antibiotic therapy duration in US adults with sinusitis. JAMA Intern Med 2018;178:julio. [Ref.ID 102480]

Zost SJ, Parkhouse K, Gumina ME, Kim K, Díaz Pérez S, Wilson PC, Treanor JJ, Sant AJ, Cobey S, Hensley SE. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains . Proceedings of the National Academy of Sciences of the United States of America 2017:6 de noviembre. [Ref.ID 102123]

Moser W, Schindler C, Keiser J. Efficacy of recommended drugs against soil transmitted helminths: systematic review and network meta-analysis. BMJ 2017;358:j4307. [Ref.ID 102094]

Okano A, Isley NA, Boger DL. Peripheral modifications of [?[CH2NH]Tpg4]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics. Proceedings of the National Academy of Sciences of the United States of America 2017:13 de marzo. [Ref.ID 101615]

Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim Y-S, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr M-B, for the MODIFY I and MODIFY II Investigators. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med 2017;376:305-17. [Ref.ID 101394]

Anónimo. Malaria drug fails in four patients treated In Britain, clinical report shows. DIA Daily 2017:7. [Ref.ID 101385]

Anónimo. Délamanid et tuberculose pulmonaire multirésistante. Prescrire 2017;37:10. [Ref.ID 101359]

Almendrala A. The success of HIV treatment is increasing the risk of drug-resistance. And the threat is growing.. The Huffington Post 2016:1. [Ref.ID 100995]

Anónimo. Fosfomycin for UTIs. Drug Ther Bull 2016;54:114-7. [Ref.ID 100882]

Anónimo. Ibalizumab shows promising results treating multi-drug-resistant HIV. DIA Daily 2016:4. [Ref.ID 100869]

Sheldon T. Saving antibiotics for when they are really needed: the Dutch example. BMJ 2016;354:i4192. [Ref.ID 100707]

Diacon AH, van der Merwe L, Barnard M, von Groote-Bidlingmaier F, Lange C, García-Basteiro AL, Sevene E, Ballell L, Barros-Aguirre D. ß-lactams against tuberculosis — New trick for an old dog?. N Engl J Med 2016;375:393-4. [Ref.ID 100492]

Owen J. Pay drug companies $1bn for each new antibiotic, says report. BMJ 2016;353:i2863. [Ref.ID 100427]